EUVIMEDEUVIMED entdecken
Vergleichsstudie

Mitral valve repair versus bioprosthetic replacement outcomes in patients with rheumatic disease over 60: Propensity score–matching results

Wenbo Zhang, Tiange Luo, Fei Meng, Baiyu Tian, Jintao Fu, Fei Li, Yichen Zhao, Qing Ye, Jinren Du, Xiaoming Li, Yuqing Jiao, Junhui Sun und 3 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2025

DOI: 10.1016/j.jtcvs.2025.03.027 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025. Verfasst von Wenbo Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Bioprosthesis, Rheumatic Heart Disease, Heart Valve Prosthesis Implantation, Mitral Valve. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Capital Health Research and Development of Special Fund, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rheumatic mitral valve disease remains a significant health issue in developing countries, especially among elderly patients with severe valvular abnormalities. The optimal surgical intervention-mitral valve repair versus bioprosthetic mitral valve replacement-for patients aged more than 60 years is debated because of limited studies in this age group. We aimed to compare mid- to long-term outcomes of mitral valve repair and bioprosthetic mitral valve replacement in elderly patients with rheumatic mitral valve disease. METHODS: We retrospectively analyzed patients aged 60 years or more who underwent mitral valve repair or bioprosthetic mitral valve replacement at Anzhen Hospital from January 2011 to June 2023. Propensity score matching was used to balance the groups. Kaplan-Meier survival analysis assessed mid- to long-term survival and reoperation rates. Subsequently, the hazard ratio for late mortality and the subdistribution hazard ratio for reoperation, considering death as a competing risk, were calculated. RESULTS: The study included 981 patients, with 317 in the mitral valve repair group and 664 in the bioprosthetic mitral valve replacement group. After propensity score matching, 254 patients from each group were included. After propensity score matching, patients had a median age of 64 years (interquartile range, 6 years). The mitral valve repair group had significantly shorter operative times, less need for blood transfusions, and lower perioperative reoperation rates. At a median follow-up of 4.8 years, patients undergoing mitral valve repair had comparable late mortality compared with bioprosthetic mitral valve replacement (hazard ratio, 0.637; 95% CI, 0.355-1.143; P = .130). Valve-related reoperation rates and adverse events, except for severe mitral regurgitation, were similar between groups. CONCLUSIONS: Among patients aged more than 60 years with rheumatic mitral valve disease, valve repair is associated with comparable mid- to long-term survival and perioperative mortality when compared with bioprosthetic valve replacement. Mitral valve repair is regarded as an optional surgical intervention for patients aged more than 60 years who have experienced rheumatic mitral valve disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BioprosthesisRheumatic Heart DiseaseHeart Valve Prosthesis ImplantationMitral ValveHeart Valve ProsthesisMitral Valve AnnuloplastyMitral Valve InsufficiencyHumansMaleFemaleRetrospective StudiesMiddle AgedPropensity ScoreAgedReoperationTreatment OutcomeTime FactorsRisk FactorsAge FactorsPostoperative ComplicationsRisk Assessment

Stichwörter der Autor:innen

bioprosthetic valvemitral valve repairmitral valve replacementoutcomerheumatic mitral valve disease

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Department of Interventional Echocardiography, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address: jiangangwang@ccmu.edu.cn.

Förderung

  • Capital Health Research and Development of Special Fund
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Luo, T., Meng, F., Tian, B., Fu, J., Li, F., Zhao, Y., Ye, Q., Du, J., Li, X., Jiao, Y., Sun, J., Zhou, M., Meng, X., & Wang, J. (2025). Mitral valve repair versus bioprosthetic replacement outcomes in patients with rheumatic disease over 60: Propensity score–matching results. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2025.03.027

Vancouver

Zhang W, Luo T, Meng F, Tian B, Fu J, Li F, et al. Mitral valve repair versus bioprosthetic replacement outcomes in patients with rheumatic disease over 60: Propensity score–matching results. The Journal of Thoracic and Cardiovascular Surgery. 2025. doi:10.1016/j.jtcvs.2025.03.027

BibTeX
@article{Zhang2025,
  author = {Zhang, Wenbo and Luo, Tiange and Meng, Fei and Tian, Baiyu and Fu, Jintao and Li, Fei and Zhao, Yichen and Ye, Qing and Du, Jinren and Li, Xiaoming and Jiao, Yuqing and Sun, Junhui and Zhou, Min and Meng, Xu and Wang, Jiangang},
  title = {Mitral valve repair versus bioprosthetic replacement outcomes in patients with rheumatic disease over 60: Propensity score–matching results},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2025},
  doi = {10.1016/j.jtcvs.2025.03.027}
}
Kostenlos starten →